TABLE 3.

Adverse Events in the Capecitabine, XELOX, and PF Arms During the Total Therapy

Characteristic	Any Grade			Grade ≥3
	Capecitabine (n = 80), No. (%)	XELOX (n = 85), No. (%)	PF (n = 81), No. (%)	Capecitabine (n = 80), No. (%)	XELOX (n = 85), No. (%)	PF (n = 81), No. (%)
Any	74 (92.5)	85 (100)	81 (100)	23 (28.8)	31 (36.5)	37 (45.7)
GI
Nausea	63 (78.8)	72 (84.7)	73 (90.1)	3 (3.8)	1 (1.2)	4 (4.9)
Abdominal distension	12 (15)	22 (25.9)	27 (33.3)	1 (1.3)	0	0
Anorexia	7 (8.8)	13 (15.3)	14 (17.3)	0	1 (1.2)	2 (2.5)
Diarrhea	3 (3.8)	6 (7.1)	6 (7.4)	0	1 (1.2)	0
Hematologic
Leukopenia	44 (55)	61 (71.8)	64 (79)	2 (2.5)	6 (7.1)	17 (21)
Anemia	11 (13.8)	12 (14.1)	21 (25.9)	0	1 (1.2)	2 (2.5)
Thrombocytopenia	9 (11.3)	16 (18.8)	19 (23.5)	2 (2.5)	4 (4.7)	6 (7.4)
Bone marrow inhibition	0	0	3 (3.7)	0	0	2 (2.5)
Radiation induced
Esophageal pain	36 (45)	40 (47.1)	27 (33.3)	6 (7.5)	2 (2.4)	4 (4.9)
Esophagitis	32 (40)	26 (30.6)	35 (43.2)	2 (2.5)	1 (1.2)	1 (1.2)
Pneumonitis	8 (10)	4 (4.7)	5 (6.2)	6 (7.5)	3 (3.5)	5 (6.2)
Dermatitis	1 (1.3)	0	2 (2.5)	0	0	1 (1.2)
Esophagotracheal fistula	1 (1.3)	3 (3.5)	0	1 (1.3)	3 (3.5)	0
Neurologic
Peripheral neuropathy	6 (7.5)	43 (50.6)	35 (43.2)	0	3 (3.5)	1 (1.2)
Constitutional symptoms
Pneumonitis	19 (23.8)	26 (30.6)	17 (21)	12 (15)	11 (12.9)	12 (14.8)
Fever	10 (12.5)	13 (15.3)	10 (12.3)	0	1 (1.2)	0
Fatigue	6 (7.5)	5 (5.9)	3 (3.7)	0	0	0
Skin and mucosa
Hand-foot syndrome	20 (25)	22 (25.9)	4 (4.9)	0	1 (1.2)	0
Mucositis	7 (8.8)	11 (12.9)	26 (32.1)	1 (1.3)	2 (2.4)	7 (8.6)

Abbreviations: PF regimen, fluorouracil plus cisplatin; XELOX regimen, capecitabine plus oxaliplatin.